UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000003928 |
|---|---|
| Receipt number | R000004707 |
| Scientific Title | A clinical investigation of SM-01 stenting versus balloon angioplasty for the treatment of superficial femoral artery disease. |
| Date of disclosure of the study information | 2010/07/20 |
| Last modified on | 2017/05/12 17:10:05 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A clinical investigation of SM-01 stenting versus balloon angioplasty for the treatment of superficial femoral artery disease.
Acronym
SM-01
Scientific Title
A clinical investigation of SM-01 stenting versus balloon angioplasty for the treatment of superficial femoral artery disease.
Scientific Title:Acronym
SM-01
Region
| Japan |
Condition
Condition
Patient with intermittent claudication who shows no sign of improvement with exercise or drug treatment. The SFA lesion(s) should be de novo or restenotic (one long or multiple, serial native lesions with total length >= 40 mm and <= 150 mm).
Classification by specialty
| Cardiology | Vascular surgery | Radiology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The main objective is to evaluate the safety and efficacy of SM-01 stenting for the treatment of SFA lesions as compared to PTA.If SM-01 is used in a PTA-bailout patient, the case will be assessed separately.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Non-TVF(Target-vessel failure) rate at 1-year follow-up
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Device,equipment |
Interventions/Control_1
STENT
Interventions/Control_2
PTA
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1. Age >= 20 years.
2. Symptomatic leg ischemia by Rutherford Classification (category1, 2, or 3).
3. Lesion length >= 40 mm to <= 150 mm. (must be treatable with no more than two SM-01 stents. Overlap should be about 1cm if two stents are used)
4. Reference vessel diameter (RVD) >= 4.0 mm and <= 7.0 mm.
5. All lesions are to be located >= 3.0 cm proximal to the superior edge of the patella, and >= 1.0 cm distal to the SFA / PFA bifurcation.
6. >= 50% stenosis or total occlusion.
7. Patent infrapopliteal and popliteal arteries, i.e., single-vessel runoff or better with at least one of three vessels patent (< 50% stenosis) to the ankle or foot.
8. Patient or legally authorized representative must provide written informed consent prior to initiation of study procedures.
9. A patient with bilateral obstructive SFA disease is eligible for enrollment into the study. If a patient with bilateral disease is enrolled, the target limb will be the more severe limb. The more severe limb will be selected according to clinical symptomatology. If clinical symptomatology is similar, the more clinically severe lesion will be selected. The contralateral procedure should not be done until at least 30 days after the index procedure of the more severe limb was attempted.
Key exclusion criteria
1. Recent hemorrhagic disease within the past 3 months.
2. Aneurysm in the SFA or popliteal artery.
3. Acute limb occlusion.
4. Procedures which are pre-determined to require stent-in-stent placement to obtain patency, such as severe calcification which is resistant to stenting, or for in-stent restenosis.
5. Poor iliac or common femoral "inflow".(However, intervention to restore adequate blood flow prior to the treatment of the study lesion is allowed.)
6. Known allergies to aspirin, heparin, or ticlopidine, or bleeding diathesis.
7. Patients unable or unwilling to tolerate anticoagulant or antiplatelet therapy.
8. Patients unable or unwilling to tolerate contrast agents used in intravascular procedures.
9. Allergic to nitinol or tantalum.
10. Women who are pregnant or lactating, or of child bearing potential, or with a desire to be a parent during the study period.
11. Significant vessel tortuosity or other parameters prohibiting access to the lesion or which would prevent delivery of the stent device.
12. Revascularization involving the same limb 30 days prior to the index procedure or a planned re-vascularization within 30 days after the index procedure.
13. Previously implanted stent(s) at the same site in the artery to be treated.
14. Requiring stent placement in the distal SFA or popliteal artery.
15. Presence of a femoral artificial graft.
16. History of participating in any other clinical study within 1 year.
17. Life expectancy less than 3 years, or any other factors preventing clinical follow-up.
18. Receiving dialysis or immunosuppressant therapy
19. Serum creatinine level >= 2.0 mg/dL before procedure.
20. A principal investigator or a co-principal investigator determines that patient is unsuitable for this study.
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Shinsuke Nanto |
Organization
Graduate School of Medicine/Faculty of Medicine, Osaka University
Division name
Advanced Cardiovascular Therapeutics
Zip code
Address
2-15, Yamadaoka, Suita-shi, Osaka, Japan
TEL
06-6879-3441
s.nanto@gmail.com
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Iizumi Misuzu |
Organization
Johnson and Johnson K.K. Medical Company
Division name
Clinical Operation
Zip code
Address
5-2, Nishi-kanda 3-chome, Chiyoda-ku, Tokyo, Japan
TEL
03-4411-6789
Homepage URL
MIIZUMI@its.jnj.com
Sponsor or person
Institute
Johnson and Johnson K.K. Medical Company
Institute
Department
Personal name
Funding Source
Organization
Johnson and Johnson K.K. Medical Company
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2010 | Year | 07 | Month | 20 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2010 | Year | 03 | Month | 25 | Day |
Date of IRB
Anticipated trial start date
| 2010 | Year | 07 | Month | 01 | Day |
Last follow-up date
| 2014 | Year | 08 | Month | 18 | Day |
Date of closure to data entry
| 2014 | Year | 09 | Month | 30 | Day |
Date trial data considered complete
| 2014 | Year | 11 | Month | 19 | Day |
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2010 | Year | 07 | Month | 20 | Day |
Last modified on
| 2017 | Year | 05 | Month | 12 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004707
